EHA 2026 | Interview mit Professor Wang Liang vom Beijing Tongren Hospital der Capital Medical University: CD19/CD22 Dual-Target CAR-T-Zelltherapie bringt neuen Durchbruch bei rezidiviertem/refraktärem großzelligem B-Zell-Lymphom – MedSci
EHA 2026 | 专访首都医科大学附属北京同仁医院王亮教授：CD19/CD22 双靶点 CAR-T 为复发/难治大 B 细胞淋巴瘤带来新突破 梅斯医学 MedSci
Vollstaendiger Artikelinhalt
{{ if item. readStatus! = 1 }} {{/if}} {{ if item. readStatus == 1 }} {{/if}} {{ if item. hrefUrl }} {{item. messageTitle}} {{else}} {{item. messageTitle}} {{/if}} {{ if item. hrefUrl || item. messageContent. length < 60 }} Erweitern {{else}} Erweitern {{/if}} Reduzieren {{ if item. hrefUrl }} {{item. messageContent}} {{else}} {{item. messageContent}} {{/if}} {{ item. cardName }} {{if item. expired}} Abgelaufen {{else}} {{ item. endTime. split(' ') }}Abgelaufen {{/if}} {{if item. expired}} {{else}} {{if item. propertyName == 'Kursmitgliedschaft'}} {{else}} {{/if}} {{/if}} {{if item. expired}} {{else}} {{/if}}
Haeufig gestellte Fragen
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
